Taylor Harvey

Wyden Disappointed in Multi-Million Dollar Windfall for Drug Makers Instead of Care for Pregnant Women in Opioid Conference Report

Conference Also Failed to Improve Transparency on Federal Advisory Panels

WASHINGTON – Senate Finance Committee Ranking Member Ron Wyden, D-Ore., today expressed disappointment in the results of the bicameral conference meeting on legislation to address the national opioid epidemic.

By: 
Taylor Harvey

Wyden Proposes Cap on Prescription Drug Costs

Ranking Finance Democrat Says Americans Shouldn’t Have to Risk Financial Ruin to Receive Treatment

WASHINGTON – Senate Finance Committee Ranking Member Ron Wyden, D-Ore., today introduced a bill to protect seniors in Medicare from high out-of-pocket costs in Part D plans.

By: 
Taylor Harvey

Data Behind The Sovaldi Report: Wyden-Grassley Investigation Looks at Drug Costs in Every State Medicaid Program

As Part of a Comprehensive, Bipartisan Report on the High Cost of Hep C Drugs, Senior Finance Members Collected Data on Drug Costs, Prescription Volume, and Patients Treated in All 50 States, D.C. State Medicaid Programs Imposed Access Restrictions Due to Budget Constraints, Yet Sovaldi Still Dominated Drug Spending

WASHINGTON – An investigation released earlier this month by Senate Finance Committee Ranking Member Ron Wyden, D-Ore., and Senator Chuck Grassley, R-Iowa, a senior member of the committee, demonstrated the significant financial impact that Gilead Sciences Inc.’s hepatitis C drug Sovaldi and its

By: 
Taylor Harvey

Wyden-Grassley Sovaldi Investigation Finds Revenue-Driven Pricing Strategy Behind $84,000 Hepatitis Drug

18-Month Investigation Reveals a Pricing and Marketing Strategy Designed to Maximize Revenue with Little Concern for Access or Affordability Report Includes Landmark Release of Medicaid Data: In 2014, More than $1 Billion Spent by Medicaid Programs on Sovaldi Treated Less than 2.4 Percent of Enrolled Patients with Hepatitis C Medicare Spent More on Gilead Hepatitis C Drugs in the First Half of 2015 than in All of 2014

WASHINGTON – Senate Finance Committee Ranking Member Ron Wyden, D-Ore., and senior committee member Chuck Grassley, R-Iowa, today released the results of an 18-month investigation into the pricing and marketing of Gilead Sciences’ Hepatitis C drug Sovaldi and its second-wave successor, Harvoni.

By: 
Taylor Harvey

Wyden Highlights GAO Report Showing E-Cigarettes Do Not Lower Smoking Rates‏

While E-Cigarette Use Spikes Among Teens and Others, Conventional Smoking Rates Appear Unaffected

WASHINGTON – Senate Finance Committee Ranking Member Ron Wyden, D-Ore., today highlighted findings from a Government Accountability Office (GAO) reportshowing the rising use of electronic cigarettes has not lowered the rate of conventional smoking, as measured by federal excise tax revenue.

By: 
Taylor Harvey

Wyden Cheers Launch of Medicare Care Choices Demonstration

CMS Pilot Program Gives Patients Flexibility to Receive Hospice Care without Forgoing Curative Treatment

WASHINGTON – Senate Finance Committee Ranking Member Ron Wyden, D-Ore., today applauded the Centers for Medicare and Medicaid Services (CMS) for their launch of the Medicare Care Choices Model (MCCM) demonstration, which will enable beneficiaries to continue receiving curative care while enrollin

By: 
Taylor Harvey

Pages

Subscribe to Taylor Harvey